Division of AIDS Clinical Trials Networks Recompetition for 2020–2027 – Comments and Recommendations from TAG
TAG’s comments on the Divisions of AIDS (DAIDS) in advance of the recompetition of its clinical trials networks.
TAG Letter to House E&C Committee Opposing “Right to Try” Bills
TAG’s comments to the Health Subcommittee of the U.S. House of Representatives Energy and Commerce Committee, in association with its hearing, “Examining Patient Access to Investigational Drugs,” and the deliberations of H.R. 1020, the Compassionate Freedom of Choice Act of 2017, and S. 204, the Right to Try Act of 2017.
HIV Research in the Era of PrEP: The Implications of TDF/FTC for Biomedical Prevention Trials
September 27, 2017 – The effectiveness of pre-exposure prophylaxis (PrEP) with the antiretroviral drug combination TDF/FTC (Truvada) raises questions regarding the design and conduct of trials of other candidate biomedical HIV prevention interventions, such as vaccines, passive immunization and alternative forms…
Advocacy organizations celebrate results as UnitedHealthcare swiftly reverses discriminatory PrEP practices
Fourteen health and social justice organizations from across the U.S. wish to celebrate the people-powered effort behind UnitedHealthcare responding so swiftly to demands that they improve access to the HIV drug Truvada for pre-exposure prophylaxis (PrEP)
TAG’s Annual Pipeline Report: Promising New HIV, TB & HCV Drugs and Diagnostics
Treatment Action Group (TAG) announces the launch of its annual research and development landscape analysis: The Pipeline Report: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.
Research Toward a Cure and Immune-Based Therapies
July 2017 By Richard Jefferys INTRODUCTION The research effort to cure HIV infection has continued to expand over the past year. The National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH) announced the…
Preventive Technologies: Antiretroviral and Vaccine Development
July 2017 By Jeremiah Johnson and Richard Jefferys INTRODUCTION Recent advances in the research, development, and implementation of biomedical HIV prevention—primarily in the form of treatment as prevention (TasP) and tenofovir disoproxil fumarate (TDF)/ emtricitabine (FTC) as pre-exposure prophylaxis (PrEP)—already…
The Antiretroviral Pipeline
July 2017 By Tim Horn INTRODUCTION The antiretroviral (ARV) pipeline remains robust, with several drugs, coformulations, and biologics currently in Phase II and III stages of development. The trends are clear: maximizing the safety and efficacy of standard three-drug regimens;…
HIV Activist Learning Module 1: What is in Our HIV Prevention Toolbox?
Objectives for Module 1: Discuss the difference between HIV prevention for HIV-negative people, HIV prevention for people living with HIV, and HIV testing Discuss the evidence-based HIV prevention options we have available Overview of new tools in development In many…
HIV Activist Learning Module 2: What is the State of Our National HIV Prevention Efforts?
Objectives for Module 2: Discuss what HEALTH INDICATORS are, what they are not, and why they are important Look at some of the current indicators and relevant research to see how well we’re doing with HIV prevention in key populations…